Cellia Science

Our mid-year update showcases a remarkable first half of 2024, with substantial product development and commercialization progress, new private investments, and regulatory advancement. We also welcomed our first institutional investor to the VIC Investor Network, marking a significant milestone. Read the full update to discover our portfolio companies' exciting strides and the promising outlook for the remainder of the year. https://hubs.ly/Q02KCW9c0

Our Annual Report Executive Summary provides an overview of the significant progress made across the VIC ecosystem in 2023 and a preview of our plans for 2024. https://hubs.ly/Q02lQL4j0 #annualreport #lifescience #medtech

Passionate about advancements in healthcare? Don't miss the opportunity to learn about Cellia Science and their exciting new hematology analysis technology in this recorded webinar: https://lnkd.in/eeMxjy3P. Reach out to Kelly Mabry (kelly@celliasci.com) to find out more. 

This is your last chance to register for this week's VIC Investor Network (VIN) webinar. We will explore key features and advantages of being a VIN member, plus presentations from two innovative portfolio companies, Nob Hill Therapeutics and Cellia Science. Nob Hill's DryNeb inhalation platform could revolutionize lung disease treatment, while Cellia Science brings rapid blood cell assays to clinical settings. Open to accredited investors interested in high-impact life science opportunities. Don't miss out – register now. https://hubs.ly/Q02h5rZQ0 #lifescience #investment #vc

The VIC Investor Network provides individual investors with the chance to diversify their portfolios through high-impact, high-return opportunities in venture capital stage investments. Our VIN webinar on January 24th will feature two exciting portfolio companies, Cellia Science and Nob Hill Therapeutics. Register below to learn more. https://hubs.ly/Q02frsV70 #venturecapital #investor #startup

In our first VIN webinar of the new year (1/24), we'll showcase two innovative portfolio companies. Cellia Science uses label-free technology for rapid and accurate blood cell assays in clinical settings and Nob Hill Therapeutics has developed a dry powder nebulizer (DryNeb) inhalation drug delivery platform. Join us on January 24th to delve into these transformative technologies with the potential to revolutionize their respective fields. https://hubs.ly/Q02fQ-b60 #investor #lifescience #vc